Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
$5.26
-3.5%
$4.52
$2.25
$7.99
$133.81M0.53224,383 shs146,954 shs
LENSAR, Inc. stock logo
LNSR
LENSAR
$3.43
+5.2%
$3.85
$1.80
$5.30
$39.10M0.4739,741 shs44,877 shs
Nephros, Inc. stock logo
NEPH
Nephros
$2.19
$2.54
$1.13
$4.04
$23.08M1.314,162 shs476 shs
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
$0.02
-18.7%
$0.02
$0.00
$0.03
$21.33M0.99323,863 shs23,850 shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
-2.68%+21.79%+16.95%+26.16%-4.22%
LENSAR, Inc. stock logo
LNSR
LENSAR
+2.52%+6.54%-6.05%-9.44%+25.38%
Nephros, Inc. stock logo
NEPH
Nephros
+3.79%+10.05%+0.46%-38.39%+54.77%
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
+4.55%-4.56%+9.52%0.00%-9.80%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
3.9479 of 5 stars
3.55.00.00.03.64.20.6
LENSAR, Inc. stock logo
LNSR
LENSAR
2.9293 of 5 stars
3.55.00.00.02.62.50.0
Nephros, Inc. stock logo
NEPH
Nephros
N/AN/AN/AN/AN/AN/AN/AN/A
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
3.00
Buy$18.50251.71% Upside
LENSAR, Inc. stock logo
LNSR
LENSAR
3.00
Buy$8.00133.24% Upside
Nephros, Inc. stock logo
NEPH
Nephros
N/AN/AN/AN/A
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
N/AN/AN/AN/A

Current Analyst Ratings

Latest NEPH, SNWV, LNSR, and DCTH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/27/2024
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$18.00 ➝ $20.00
3/19/2024
LENSAR, Inc. stock logo
LNSR
LENSAR
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$8.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
$2.07M64.64N/AN/A$0.72 per share7.31
LENSAR, Inc. stock logo
LNSR
LENSAR
$42.16M0.93N/AN/A$2.97 per share1.15
Nephros, Inc. stock logo
NEPH
Nephros
$14.24M1.62N/AN/A$0.80 per share2.74
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
$20.40M1.05N/AN/A($0.04) per share-0.47

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
-$47.68M-$2.97N/AN/AN/A-2,308.86%-563.60%-111.13%5/27/2024 (Estimated)
LENSAR, Inc. stock logo
LNSR
LENSAR
-$14.38M-$1.79N/AN/A-34.11%-40.53%-21.83%5/20/2024 (Estimated)
Nephros, Inc. stock logo
NEPH
Nephros
-$1.58M-$0.15N/AN/A-11.06%-18.25%-14.29%5/8/2024 (Estimated)
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
-$25.81M-$0.03N/AN/A-126.52%N/A-32.63%5/10/2024 (Estimated)

Latest NEPH, SNWV, LNSR, and DCTH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/26/2024Q4 23
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
-$0.67-$0.48+$0.19-$0.48$0.48 million$0.54 million    
3/21/2024Q4 2023
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
N/A$0.03+$0.03$0.03N/A$6.99 million
3/7/2024Q4 2023
Nephros, Inc. stock logo
NEPH
Nephros
N/A-$0.06-$0.06-$0.06N/A$3.25 million    
3/4/202412/31/2023
LENSAR, Inc. stock logo
LNSR
LENSAR
-$0.22-$0.22N/A-$0.35N/A$12.11 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
N/AN/AN/AN/AN/A
LENSAR, Inc. stock logo
LNSR
LENSAR
N/AN/AN/AN/AN/A
Nephros, Inc. stock logo
NEPH
Nephros
N/AN/AN/AN/AN/A
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
N/A
2.26
2.06
LENSAR, Inc. stock logo
LNSR
LENSAR
N/A
3.99
2.64
Nephros, Inc. stock logo
NEPH
Nephros
N/A
3.98
2.81
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
N/A
0.15
0.11

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
61.12%
LENSAR, Inc. stock logo
LNSR
LENSAR
40.15%
Nephros, Inc. stock logo
NEPH
Nephros
41.10%
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
42.53%

Insider Ownership

CompanyInsider Ownership
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
17.94%
LENSAR, Inc. stock logo
LNSR
LENSAR
38.52%
Nephros, Inc. stock logo
NEPH
Nephros
4.10%
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
16.40%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
7625.44 million20.88 millionOptionable
LENSAR, Inc. stock logo
LNSR
LENSAR
13011.40 million7.01 millionOptionable
Nephros, Inc. stock logo
NEPH
Nephros
3110.54 million10.11 millionNot Optionable
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
311.14 billion953.51 millionNot Optionable

NEPH, SNWV, LNSR, and DCTH Headlines

SourceHeadline
SANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2024 (Ended March 31, 2024)SANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2024 (Ended March 31, 2024)
globenewswire.com - April 10 at 8:30 AM
SANUWAVE Health Appoints Industry Veteran Peter Sorensen as Chief Financial OfficerSANUWAVE Health Appoints Industry Veteran Peter Sorensen as Chief Financial Officer
globenewswire.com - April 1 at 4:00 PM
SANUWAVE Health, Inc. (PNK:SNWV) Q4 2023 Earnings Call TranscriptSANUWAVE Health, Inc. (PNK:SNWV) Q4 2023 Earnings Call Transcript
msn.com - March 25 at 7:14 PM
SANUWAVE Announces Record Q4 and FY2023 RevenueSANUWAVE Announces Record Q4 and FY2023 Revenue
globenewswire.com - March 22 at 6:00 AM
SANUWAVE Will Host a Conference Call on March 22, 2024 at 8:30 AM (ET) to Present the Q4 and FY2023 Financial ResultsSANUWAVE Will Host a Conference Call on March 22, 2024 at 8:30 AM (ET) to Present the Q4 and FY2023 Financial Results
globenewswire.com - March 20 at 7:00 AM
SANUWAVE Health, Inc.: SANUWAVE Health Reports Stockholder Approval of SEPA Merger at Special Meeting of StockholdersSANUWAVE Health, Inc.: SANUWAVE Health Reports Stockholder Approval of SEPA Merger at Special Meeting of Stockholders
finanznachrichten.de - February 23 at 10:24 AM
SANUWAVE Health Stock (OTC:SNWV) Dividends: History, Yield and DatesSANUWAVE Health Stock (OTC:SNWV) Dividends: History, Yield and Dates
benzinga.com - February 23 at 10:24 AM
SANUWAVE Health Reports Stockholder Approval of SEPA Merger at Special Meeting of StockholdersSANUWAVE Health Reports Stockholder Approval of SEPA Merger at Special Meeting of Stockholders
globenewswire.com - February 22 at 5:00 PM
SEP Acquisition shareholders approve Sanuwave SPAC mergerSEP Acquisition shareholders approve Sanuwave SPAC merger
msn.com - February 1 at 7:46 PM
Sanuwave Health Announces New Financial Obligation RegistrationSanuwave Health Announces New Financial Obligation Registration
msn.com - January 26 at 10:25 PM
EQS-News: SANUWAVE Announces Special Meeting of Stockholders to Vote on Business Combination with SEP Acquisition Corp. (Nasdaq: SEPA)EQS-News: SANUWAVE Announces Special Meeting of Stockholders to Vote on Business Combination with SEP Acquisition Corp. (Nasdaq: SEPA)
markets.businessinsider.com - January 22 at 8:28 AM
SANUWAVE Announces Special Meeting of Stockholders to Vote on Business Combination with SEP Acquisition Corp. (Nasdaq: SEPA)SANUWAVE Announces Special Meeting of Stockholders to Vote on Business Combination with SEP Acquisition Corp. (Nasdaq: SEPA)
finance.yahoo.com - January 22 at 8:28 AM
Sanuwave Health sees Q4 record revenue $6.6M-$6.8M, up 20% Y/YSanuwave Health sees Q4 record revenue $6.6M-$6.8M, up 20% Y/Y
msn.com - January 10 at 12:43 PM
SANUWAVE Health Announces Preliminary Revenue Results for the Fourth Quarter and Fiscal Year 2023, Ended December 31, 2023SANUWAVE Health Announces Preliminary Revenue Results for the Fourth Quarter and Fiscal Year 2023, Ended December 31, 2023
finance.yahoo.com - January 10 at 7:42 AM
SANUWAVE Health, Inc.: SANUWAVE Announces Q3 2023 Financial ResultsSANUWAVE Health, Inc.: SANUWAVE Announces Q3 2023 Financial Results
finanznachrichten.de - November 11 at 1:34 AM
SANUWAVE Health GAAP EPS of -$0.03, revenue of $5M; initiates Q4 outlookSANUWAVE Health GAAP EPS of -$0.03, revenue of $5M; initiates Q4 outlook
msn.com - November 10 at 10:33 AM
SANUWAVE Will Host a Conference Call on November 10, 2023 at 8:00 AM (ET) to Present the Q3 2023 Financial ResultsSANUWAVE Will Host a Conference Call on November 10, 2023 at 8:00 AM (ET) to Present the Q3 2023 Financial Results
finance.yahoo.com - November 8 at 8:20 PM
SANUWAVE Health Announces Preliminary Revenue Results for the Third Quarter Ended September 30, 2023SANUWAVE Health Announces Preliminary Revenue Results for the Third Quarter Ended September 30, 2023
finance.yahoo.com - October 10 at 9:30 AM
Sanuwave to go public in $127.5M SPAC mergerSanuwave to go public in $127.5M SPAC merger
massdevice.com - August 24 at 5:32 PM
Sanuwave Health eyes Nasdaq listing, announces merger with SEP AcquisitionSanuwave Health eyes Nasdaq listing, announces merger with SEP Acquisition
msn.com - August 23 at 5:25 PM
SANUWAVE Health, Inc., a Leading Provider of FDA Approved Next-Generation Wound Care Products, Enters into a Merger Agreement with Sweat Equity Partners and Mercury Life Sciences-affiliated SEP Acquisition Corp., a Nasdaq-Listed CompanySANUWAVE Health, Inc., a Leading Provider of FDA Approved Next-Generation Wound Care Products, Enters into a Merger Agreement with Sweat Equity Partners and Mercury Life Sciences-affiliated SEP Acquisition Corp., a Nasdaq-Listed Company
finance.yahoo.com - August 23 at 5:25 PM
SANUWAVE Health, Inc.: SANUWAVE Announces Q2 2023 Financial ResultsSANUWAVE Health, Inc.: SANUWAVE Announces Q2 2023 Financial Results
finanznachrichten.de - August 11 at 8:09 AM
SANUWAVE Announces Q2 2023 Financial ResultsSANUWAVE Announces Q2 2023 Financial Results
finance.yahoo.com - August 11 at 8:09 AM
SANUWAVE Will Host a Live Conference Call on August 11, 2023 at 8:30 AM (EDT) to Present Its Q2 2023 Financial ResultsSANUWAVE Will Host a Live Conference Call on August 11, 2023 at 8:30 AM (EDT) to Present Its Q2 2023 Financial Results
finance.yahoo.com - August 9 at 8:35 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Delcath Systems logo

Delcath Systems

NASDAQ:DCTH
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
LENSAR logo

LENSAR

NASDAQ:LNSR
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
Nephros logo

Nephros

NASDAQ:NEPH
Nephros, Inc. engages in development and sale of high performance water solutions to the medical and commercial markets in the United States. The company operates in two segments: Water Filtration and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells medical device products for patients with renal disease, including a second generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it manufactures and sells water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and Nanoguard brands for the food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.
SANUWAVE Health logo

SANUWAVE Health

OTCMKTS:SNWV
SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's pulsed acoustic cellular expression systems, including dermaPACE system for treating diabetic foot ulcers and other chronic wounds; orthoPACE system for treating tendinopathies and acute and nonunion fractures; and Profile is used to provide therapeutic treatment of musculoskeletal conditions. Its portfolio of wound treatment solutions provides patients with a noninvasive technology that boosts the body's normal healing and tissue regeneration processes. In addition, the company offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds. SANUWAVE Health, Inc. was founded in 2004 and is headquartered in Eden Prairie, Minnesota.